Poseida Therapeutics Inc (PSTX)

[jondoeuk]

As of the cutoff date, the trial had enrolled a total of nine patients with mCRPC. Five were treated with Dose A (an average of about 20M cells), and four with Dose B (an average of about 60M cells). Patients were heavily pre-treated, having received an average of six prior lines of therapy. Five showed measurable declines in PSA levels, with three showed a greater than 50% decline. One demonstrated evidence of complete tumour elimination and remains in a durable response of greater than five months at the time of this presentation https://poseida.com/wp-content/uploads/2021/08/CAR-TCR-Summit-2021_P-PSMA-101-Update_08312021.pdf